(Forbes)Renewable energy developer SunEdison and specialty drug manufacturer Valeant Pharmaceuticals can be slapped with a lot of the same labels as they’ve tumbled in 2015. Call them hedge fund hotels or financial engineering Frankensteins, their complexity and leverage are being looked at with fresh eyes by both rank-and-file investors and hedge fund billionaires.
But if SunEdison CEO Ahmad Chatila or Valeant architect J. Michael Pearson don’t outlast their current struggles, it won’t just be because their inscrutable corporate empires reached a tipping point. In fact, it will more likely result from easy-to-see failures of governance and shareholder stewardship.
Rethinking The Collapse Of Wall Street Favorites Valeant And SunEdison
This entry was posted in Syndicated. Bookmark the permalink.
